Cardio Diagnostics Holdings, Inc. (CDIO) is a Healthcare stock trading at $1.85 (as of 2026-09-02), with a market capitalization of $5.48M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. Its Epi+Gen CHD test is designed to assess the risk of symptomatic coronary heart disease over a three-year period.
Cardio Diagnostics develops epigenetics-based blood tests that estimate a patient's three-year risk of developing coronary heart disease, and sells those test kits to cardiology clinics and reference labs. The business is still pre-scale, so the number of test orders booked, not margin expansion, is what an investor should anchor on.
The entire profit model hinges on Epi+Gen CHD becoming an adopted standard-of-care screening test in cardiology before the operating burn outlasts the company's cash runway.
Business quality (Unprofitable): Unprofitable. The company reports near-zero revenue with an operating loss roughly 280 times the top line, indicating it is still in the development and commercialization investment phase.
| Price | $1.85 |
| Market Cap | $5.48M |
| Price / Book | 0.74 |
| Price / Sales | 378.89 |
| FCF Yield | -108.0% |
| Revenue (TTM) | $14825.00 |
| Net Margin | -43832.5% |
| Revenue Growth (YoY) | -28.3% |
| EPS Growth (YoY) | -47.4% |
| FCF Growth (YoY) | 82.8% |
| Altman Z-Score | -3.08 (distress) |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | JANE STREET GROUP, LLC ($158502.00) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Meeshanthini V. Dogan |
| Employees | 13 |
| Country | US |
| IPO Date | 2022-01-14 |
Data as of 2026-09-02.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.